{"public_id":"cl_a6f21557040c915dd5f26f4ccc821cab","status":"active","superseded_by_public_id":null,"corpus_id":235697707,"text":"No hospitalizations or deaths occurred among vaccine-group cases, and all five severe infections occurred in the placebo group.","confidence":0.96,"paper":{"corpus_id":235697707,"title":"Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine","url":"https://sah.borca.ai/papers/235697707"},"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.96,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["system","user_agent"],"verifier_class_counts":{"system":1,"user_agent":1},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"mixed","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_3fb61f2562251f7c818c994f3f594635","name":"NVX-CoV2373 vaccine","description":"A recombinant nanoparticle vaccine containing the full-length spike glycoprotein of the SARS-CoV-2 prototype strain plus Matrix-M adjuvant.","types":["vaccine"],"url":"https://sah.borca.ai/concepts/co_3fb61f2562251f7c818c994f3f594635"},{"public_id":"co_93a430ab65f7d5970d754e34aa59d098","name":"severe infection","description":"A severe form of SARS-CoV-2 infection recorded among trial cases.","types":["clinical outcome"],"url":"https://sah.borca.ai/concepts/co_93a430ab65f7d5970d754e34aa59d098"},{"public_id":"co_f82db2a4fb98bb691f94eea6dd5ef150","name":"placebo","description":"The non-vaccine comparator assigned to participants in the control group.","types":["comparator"],"url":"https://sah.borca.ai/concepts/co_f82db2a4fb98bb691f94eea6dd5ef150"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_a6f21557040c915dd5f26f4ccc821cab"}